123,878 Shares in Johnson & Johnson (NYSE:JNJ) Bought by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. bought a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 123,878 shares of the company's stock, valued at approximately $17,915,000.

Other large investors have also recently bought and sold shares of the company. IFS Advisors LLC grew its stake in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after purchasing an additional 100 shares during the last quarter. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $32,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $35,000. Activest Wealth Management acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $40,000. Finally, Fiduciary Advisors Inc. acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $43,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mark A. Weinberger purchased 1,000 shares of the company's stock in a transaction dated Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent research reports. Raymond James lowered their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Guggenheim raised their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a "neutral" rating in a report on Monday, February 3rd. Barclays raised their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a report on Tuesday, January 28th. Citigroup decreased their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a report on Wednesday, December 11th. Finally, Leerink Partners decreased their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $171.33.

Johnson & Johnson Stock Down 0.1 %

JNJ traded down $0.20 during midday trading on Wednesday, hitting $165.22. 8,744,672 shares of the company's stock traded hands, compared to its average volume of 7,006,371. The company has a market cap of $397.79 billion, a PE ratio of 24.85, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The stock's fifty day simple moving average is $152.11 and its 200-day simple moving average is $156.19. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.29 earnings per share. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.00%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson's payout ratio is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.